多西紫杉醇+顺铂+氟尿嘧啶方案新辅助化疗治疗进展期胃癌的Meta分析

摘要

目的 系统评价多西紫杉醇+顺铂+氟尿嘧啶(DCF)方案新辅助化疗在进展期胃癌治疗中的有效性和安全性.方法 计算机检索PubMed、EMbase、The Cochrane Library、Web of Science、中国生物医学文献数据库、中国知网、万方数据库等,检索时限为从建库至2017年5月,搜集关于DCF方案新辅助化疗治疗进展期胃癌的随机对照试验和非随机对照试验,采用RevMan 5.3软件进行Meta分析.结果 共纳入8个研究,包括3个随机对照试验,5个非随机对照试验,576例进展期胃癌患者.Meta分析结果显示,DCF方案新辅助化疗联合手术组与直接手术组或其他方案新辅助化疗联合手术组相比,在根治性手术切除率、2年生存率方面差异有统计学意义,而有效率、1年生存率及术后并发症发生率方面差异无统计学意义.结论 DCF方案新辅助化疗可提高进展期胃癌的根治性手术切除率、延长患者的生存期,且不增加术后并发症的发生.%Objective To evaluate the efficacy and safety of docetaxel,cisplatin and fluorouracil (DCF) regimen in neoadjuvant chemotherapy in the treatment of advanced gastric cancer.Methods PubMed,EMbase,The Cochrane Library,Web of Science,CBM,CNKI and WanFang Data were searched from their inception to May 2017,to collect randomized controlled trials (RCTs) and non-RCTs about DCF regimen in neoadjuvant chemotherapy in treating advanced gastric cancer.A meta-analysis was performed by using RevMan 5.3 software.Results 8 studies involving 576 advanced gastric cancer patients were included,of which 3 were RCTs and the other 5 were non-RCTs.The two therapies were significantly different in the radical resection rate and 2-year survival rate,while no statistical significance occurred in the response rate,1-year survival rate and postoperative complications rate.Conclusion Neoadjuvant chemotherapy of DCF regimen can improve the radical resection rate and prolong the survival time of patients without increasing the incidence of postoperative complications.